Abstract Number: 1406 • ACR Convergence 2022
Integrative Multi-omic Phenotyping in Blood Identifies Molecular Signatures and Candidate Biomarkers of ACPA-negative Rheumatoid Arthritis
Background/Purpose: ACPA detection assays are often used for RA diagnosis due to their high specificity ( >90%). However, current ACPA assays (e.g., anti-CCP2 ELISA) have…Abstract Number: 1554 • ACR Convergence 2022
Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis
Background/Purpose: 18FDG-PET imaging can be used to directly assess vascular inflammation; however, limited access to this technology has restricted widespread adoption of this modality in…Abstract Number: 1803 • ACR Convergence 2022
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…Abstract Number: 1981 • ACR Convergence 2022
Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…Abstract Number: 2176 • ACR Convergence 2022
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin and internal organs. Cardiac involvement, pulmonary arterial hypertension (PAH), and interstitial lung…Abstract Number: 0165 • ACR Convergence 2022
Low Paraoxonase-1 Enzyme Activity in Patients with Idiopathic Inflammatory Myopathies Associates with Cancer Diagnosis
Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)- associated enzyme with antioxidative properties, which is low in activity in patients with idiopathic inflammatory myopathies…Abstract Number: 0471 • ACR Convergence 2022
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…Abstract Number: 0634 • ACR Convergence 2022
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Background/Purpose: Kidney biopsy is a gold standard for diagnosis and prognostication of lupus nephritis (LN). While interstitial fibrosis and tubular atrophy (IFTA) predict progression to…Abstract Number: 0883 • ACR Convergence 2022
Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis
Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…Abstract Number: 1130 • ACR Convergence 2022
Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics
Background/Purpose: The clinical outcome of conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable in rheumatoid arthritis (RA) patients. Thus, innovative analyses…Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…Abstract Number: 1982 • ACR Convergence 2022
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…Abstract Number: 2211 • ACR Convergence 2022
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis
Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 96
- Next Page »